T cell therapy companies develop treatments that use a patient’s own or donor-derived immune cells to recognise and attack disease. These approaches are primarily used in cancer immunotherapy, with emerging applications across autoimmune and infectious diseases.
This category includes companies working on:
Browse 48 UK T cell therapy companies below.
Near-infrared bioluminescence reagents for preclinical imaging research
Bioflares is a biotechnology company developing and supplying infraluciferin-based reagents and engineered luciferase enzymes for near-infrared bioluminescence imaging. Its patented infraluciferin substrate enables simultaneous dual-parameter imaging of two biological processes in living animals, supporting…
Generative AI platform for TCR therapy design and immune repertoire analysis
Synteny Biotechnology is a biotechnology company developing a platform that combines high-throughput TCR-antigen data generation with generative AI to design precision T cell receptor therapies for cancer. The platform addresses a critical bottleneck in the field, namely the scarcity of paired TCR-epitope interaction…
Synthetic promoter platform for precision gene expression control
Chromatin Bioscience designs synthetic promoters and gene expression control systems for cell and gene therapy developers. Its platform uses bioinformatics to identify cell-type-selective regulatory elements from the human genome, which are assembled into novel synthetic promoters enabling precise, durable and…
Next-generation lateral CAR-T therapies for refractory solid tumours
Leucid Bio Ltd is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for hard-to-treat solid tumours. Founded on over two decades of King's College London research, the platform redesigns the CAR signalling architecture to enhance T-cell potency, persistence, and tumour…
Target discovery platform and antibody-based therapies for oncology
Oxford BioTherapeutics is an Oxford-based clinical-stage oncology company discovering and developing first-in-class antibody-based cancer therapies. Its proprietary platform identifies novel membrane protein targets directly from patient tumour samples, enabling the development of ADCs, immuno-oncology antibodies,…
Robotic automation platform for scalable cell therapy manufacturing
Cellular Origins is a biotechnology company developing robotic automation systems for the industrial-scale manufacture of cell therapies. Its platform uses mobile robotics and automated sterile fluidic interconnection to link existing bioprocess instruments into fully automated, GMP-compliant manufacturing workflows.…
Programmable cell-killing particle platform for targeted therapeutic delivery
Granza Bio is a biotechnology company developing a cell-targeted delivery platform based on supramolecular attack particles, naturally occurring structures used by cytotoxic T cells and natural killer cells to deliver lethal payloads with precision. The company is engineering programmable versions of these particles,…
Engineered T cell receptor therapies for solid tumour cancers
Adaptimmune is a clinical-stage biopharmaceutical company developing engineered T cell receptor therapies targeting solid tumours. The company's T-cell platform engineers T cell receptors with enhanced affinity for cancer-associated antigens, enabling immune recognition of tumour cells that evade conventional…
Global supplier of instruments and reagents for cell research and therapy
Miltenyi Biotec is a company developing and supplying instruments, reagents and services supporting biomedical research and cell and gene therapy manufacturing. Its product portfolio spans magnetic-activated cell separation, flow cytometry, cell culture, molecular analysis and preclinical imaging, with clinical-grade…
Programmable gene control platform for advanced cell therapies
Laverock Therapeutics is a biotechnology company developing a programmable gene control platform for the creation of disease-responsive advanced therapies. The platform uses recoded microRNAs to deliver tunable, stable and multiplexed gene silencing within cell therapies, enabling enhanced precision and improved…
AI-driven T-cell receptor discovery platform for solid tumour immunotherapies
Exogene is an Oxford biotech developing TCR-based immunotherapies for solid tumours. Its platform integrates generative AI, biophysical simulation, and high-throughput TCR-antigen screening to identify rare, high-affinity cancer-specific T-cell receptors from patient tumour samples. The company develops TCR-T cell…
In vivo lentiviral CAR/TCR cell therapy platform for ovarian cancer
Akimbo Bio is an early-stage biotechnology company developing next-generation in vivo lentiviral vector technology for cell therapy. Its lead platform carries a dual CAR/TCR payload designed for direct in vivo delivery, with an initial focus on ovarian cancer. The technology uses intelligent receptor crosstalk, in…
Targeted nanoparticles for in vivo CAR-T and gene delivery
Deliver Biosciences is a biotechnology company developing targeted nanoparticle vectors for in vivo cell and gene therapies. Its delivery platform transports genetic payloads, including DNA and mRNA, into selected cell types using programmable targeting components. Its lead programme aims to engineer T cells inside…
Combinatorial stem cell screening platform for therapy development
Plasticell is a biotechnology company developing cell and gene therapies and enabling drug discovery through its proprietary platform. The technology uses bead-based combinatorial screening to test thousands of cell culture variable combinations in parallel, identifying optimised protocols for stem cell expansion,…
Specialist oncology clinical trial management for biotech and pharma
Karma Oncology is a specialist contract research organisation providing full-service and functional clinical trial management to biotechnology and pharmaceutical companies in oncology. Operating as a lean virtual CRO, the company offers clinical development planning, protocol design, site selection and activation,…
Bispecific TCR therapies targeting HLA-Class II cancer antigens
Yellowstone Biosciences is a pre-clinical biotechnology company developing bispecific T-cell receptor therapies for oncology. The company targets a novel class of HLA Class II antigens expressed across multiple cancers, with an initial programme focused on acute myeloid leukaemia. Its approach is designed to…
Pre-competitive biologics drug discovery platforms and services for partners
Alloy Therapeutics UK is the Cambridge-based research operation of Alloy Therapeutics, a biotechnology platform company providing pre-competitive drug discovery technologies and services across antibody, TCR, genetic medicine, cell therapy, peptide, and drug delivery modalities. The company offers both discovery…
Cell and gene therapy supply chain orchestration software
TrakCel is a Welsh software company providing digital orchestration platforms for the management, tracking, and control of cell and gene therapy products across clinical and commercial supply chains. Its flagship platform manages chain of identity and chain of custody for personalised therapies from sample collection…
Automated bioreactor platform for GMP cell therapy manufacturing
Aglaris is a developer of automated cell manufacturing systems for advanced therapy medicinal products. Its flagship platform integrates real-time process monitoring, single-use culture cartridges, and GMP-compliant controls to enable reproducible production of CAR-T cells, mesenchymal stem cells, and other cell types…
CAR T cell therapies for blood cancer and autoimmune disease
Autolus Therapeutics is a London-based commercial-stage biopharma developing next-generation programmed T cell therapies. Its lead product AUCATZYL (obecabtagene autoleucel) received FDA approval in November 2024 and MHRA conditional marketing authorisation in 2025 for relapsed or refractory B-cell acute lymphoblastic…